Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

Investors may react cautiously to news that NATCOPHARM's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 4.09800
forwardPE 24.11955
debtToEquity 3.01200
earningsGrowth -0.23500
revenueGrowth -0.00600
grossMargins 0.82408
operatingMargins 0.38650
trailingEps 85.89000
forwardEps 41.27000

NATCOPHARM's current ratio of 4.098 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, NATCOPHARM can comfortably cover its liabilities, reflecting a strong financial outlook.
NATCO Pharma Limited's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
NATCOPHARM's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability.
NATCOPHARM's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
NATCOPHARM's forward EPS being less than trailing EPS indicates the company's profitability is expected to decrease. This signals a potential downturn in financial performance compared to the previous year.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

Over time, price projections for NATCOPHARM have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for NATCOPHARM's continued growth.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


There were 9 transactions selling NATCOPHARM stock, with prevailing market price of 1145.661112467448.There were 2 buy transactions of NATCO Pharma Limited, with market price at 851.625.More buys than sells have been occurring around the current price levels of NATCOPHARM, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


NATCOPHARM has received a mixed set of ratings from analysts, with no clear buy or sell recommendations. This ambiguity points to an uncertain market outlook, prompting investors to seek out other financial indicators to guide their investment strategies.